POSC157 Treatment of Moderate-to-Severe Active Psoriatic Arthritis: Cost-Effectiveness Analysis and Budget Impact Analysis of Biologics and Targeted Therapies Approved in the Russian Federation
Abstract
Authors
A Rudakova D Tolkacheva V Sokolova